Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.72 |
| ▸ | POLB | P06746 | 10/20 | 0.72 |
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 5/20 | 0.61 |
| ▸ | BLM | P54132 | 3/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.61 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.61 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899866 | 1.00 | MEN1 (0.72) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3012532 | 0.84 | MEN1 (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3895249 | 0.83 | KMT2A (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3897791 | 0.83 | MEN1 (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3895245 | 0.83 | KMT2A (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL6282463 | 0.83 | KMT2A (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3897789 | 0.83 | MEN1 (1.00) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3892072 | 0.82 | PTPN12 (0.66) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3892071 | 0.82 | PTPN12 (0.66) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL3904812 | 0.81 | MEN1 (0.77) | MEN1KMT2APOLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MEN1 1562/4885KMT2A 901/4885POLB 2008/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MEN1 2869/4885KMT2A 1020/4885POLB 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.